tradingkey.logo

tradingkey.logo
怜玢


Citius Pharmaceuticals Inc

CTXR
りォッチリストに远加
0.535USD
+0.003+0.56%
終倀 11-13 16:00ET
14.69M時䟡総額
損倱額盎近12ヶ月PER

Citius Pharmaceuticals Incに぀いお 䌁業名

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

Citius Pharmaceuticals Inc プロフィヌル


䌁業コヌドCTXR
䌚瀟名Citius Pharmaceuticals Inc
䞊堎日Aug 03, 2017
最高経営責任者「CEO」Mazur (Leonard L)
埓業員数23
蚌刞皮類Ordinary Share
決算期末Aug 03
本瀟所圚地11 Commerce Dr Fl 1
郜垂CRANFORD
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号07016-3501
電話番号19089676677
りェブサむトhttps://www.citiuspharma.com/
䌁業コヌドCTXR
䞊堎日Aug 03, 2017
最高経営責任者「CEO」Mazur (Leonard L)

Citius Pharmaceuticals Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Leonard Mazur
Mr. Leonard Mazur
Executive Chairman of the Board, Chief Executive Officer, Company Secretary
Executive Chairman of the Board, Chief Executive Officer, Company Secretary
410.21K
--
Mr. Myron Z. Holubiak
Mr. Myron Z. Holubiak
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
79.69K
--
Mr. Jaime Bartushak
Mr. Jaime Bartushak
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
2.41K
--
Ms. Carol A. Webb
Ms. Carol A. Webb
Independent Director
Independent Director
473.00
--
Mr. Suren G. Dutia
Mr. Suren G. Dutia
Independent Director
Independent Director
--
--
Dr. Eugene Holuka, M.D.
Dr. Eugene Holuka, M.D.
Independent Director
Independent Director
--
--
Ms. Ilanit Allen
Ms. Ilanit Allen
Vice President - Corporate Communications and Investor Relations
Vice President - Corporate Communications and Investor Relations
--
--
Dr. Myron S. Czuczman, M.D.
Dr. Myron S. Czuczman, M.D.
Chief Medical Officer, Executive Vice President
Chief Medical Officer, Executive Vice President
--
--
Mr. Dennis M. McGrath
Mr. Dennis M. McGrath
Independent Director
Independent Director
--
--
Mr. Robert J. Smith
Mr. Robert J. Smith
Independent Director
Independent Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Leonard Mazur
Mr. Leonard Mazur
Executive Chairman of the Board, Chief Executive Officer, Company Secretary
Executive Chairman of the Board, Chief Executive Officer, Company Secretary
410.21K
--
Mr. Myron Z. Holubiak
Mr. Myron Z. Holubiak
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
79.69K
--
Mr. Jaime Bartushak
Mr. Jaime Bartushak
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
2.41K
--
Ms. Carol A. Webb
Ms. Carol A. Webb
Independent Director
Independent Director
473.00
--
Mr. Suren G. Dutia
Mr. Suren G. Dutia
Independent Director
Independent Director
--
--
Dr. Eugene Holuka, M.D.
Dr. Eugene Holuka, M.D.
Independent Director
Independent Director
--
--

よくある質問

Citius Pharmaceuticals Incの䞊䜍5名の株䞻は誰ですか


Citius Pharmaceuticals Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Leonard Mazur

Citius Pharmaceuticals IncCTXRの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Citius Pharmaceuticals Incの株匏を保有しおいる機関は150瀟あり、保有株匏の総垂堎䟡倀は玄1.71Mで、党䜓の6.32%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-1147379.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。